Trials / Completed
CompletedNCT04111666
A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101
A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Bioavailability of IV and SC AL101
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Alector Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
Detailed description
This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK, PD and Bioavailability of intravenously and sub-cutaneously administered AL101 in Healthy Volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AL101 | Active dose of AL101 |
| OTHER | Placebo | Saline solution administered as a single and multiple infusion as placebo. |
Timeline
- Start date
- 2019-12-14
- Primary completion
- 2022-06-09
- Completion
- 2022-06-09
- First posted
- 2019-10-01
- Last updated
- 2022-08-10
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04111666. Inclusion in this directory is not an endorsement.